Full-Time

Executive Director

Process Chemistry

Praxis Precision Medicines

Praxis Precision Medicines

201-500 employees

Clinical-stage biopharma developing CNS therapies

Compensation Overview

$280k - $306k/yr

+ Discretionary Quarterly Bonus + Stock Incentives + ESPP + 401(k) Match

Remote in USA

Remote

Category
Biology & Biotech (2)
,
Requirements
  • Ph.D. in Chemistry, Chemical Engineering, Pharmaceutical Sciences, or related discipline.
  • 12+ years of progressive leadership in process development and CMC strategy, with deep expertise in both early-stage and late-stage development.
  • Proven track record of leading API development and scale-up through global regulatory submissions and commercial launch.
  • Deep technical knowledge spanning small molecules and oligonucleotides, with fluency in emerging manufacturing technologies.
  • Strong leadership in global vendor and alliance management, with a history of building and sustaining high-functioning external networks.
  • Strategic thinker with exceptional problem-solving skills and the ability to drive clarity in complexity.
  • Operates with urgency, scientific rigor, and enterprise thinking to enable bold patient impact.
  • The physical and mental requirements of our roles include but are not limited to regular use of a computer, devices or other office equipment, clear communication, and occasional movement.
  • Reasonable accommodations may be made to enable individuals with disabilities to perform these functions.
Responsibilities
  • Own and drive the global API strategy across Praxis’ portfolio, ensuring scientific excellence, regulatory alignment, and supply chain scalability from IND through commercial launch.
  • Lead the design, development, and industrialization of robust, phase-appropriate drug substance processes—championing modern technologies such as continuous flow, biocatalysis, and digital process design.
  • Act as a thought leader and decision-maker in CMC governance forums, ensuring tight alignment between drug substance strategy and broader program objectives.
  • Build and lead a high-performing, multidisciplinary ecosystem of internal talent and external partners (CROs/CDMOs), holding to the highest standards of execution, accountability, and innovation.
  • Define and execute vendor strategy, including partner selection, technical oversight, contract negotiation, and performance governance.
  • Ensure seamless integration with Analytical, Formulations, Regulatory, Quality, and Clinical Supply—driving unified CMC plans that anticipate risk and accelerate timelines.
  • Represent Praxis externally with regulators, partners, and scientific communities—contributing to our reputation as a science-driven, execution-focused innovator in CNS therapeutics.
Desired Qualifications
  • Experience leading at senior corporate level in pharmaceutical industry (not explicitly present but implied)
Praxis Precision Medicines

Praxis Precision Medicines

View

Praxis Precision Medicines develops therapies for central nervous system (CNS) disorders, with a focus on conditions caused by neuronal imbalance and genetic epilepsies. Its products aim to restore balance in CNS networks by applying genetic epilepsy insights, progressing through clinical development toward potential commercialization. What sets Praxis apart is its commitment to patient-guided development, incorporating patient and caregiver needs into therapy design, alongside strategic partnerships with other healthcare entities. The company's goal is to deliver effective CNS treatments to patients and caregivers and advance collaborations that support clinical development and eventual market access.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted relutrigine NDA with PDUFA September 27, 2026, ulixacaltamide January 29, 2027.
  • $1.4B cash reserves from $575M January 2026 offering fund operations through 2028.
  • Driehaus $80.5M, Affinity $55M investments signal institutional confidence in dual launches.

What critics are saying

  • Jazz suvecaltamide approved March 15, 2026, competes directly with ulixacaltamide in $2B market.
  • FDA clinical hold on vormatrigine May 10, 2026, destroys 60% pipeline value.
  • $120M quarterly burn depletes cash by mid-2028, forces dilutive financing.

What makes Praxis Precision Medicines unique

  • Praxis translates genetic epilepsy insights into therapies for CNS neuronal imbalance.
  • Relutrigine achieves 46% motor seizure reduction in Phase 2, 30% seizure-free patients.
  • Ulixacaltamide shows positive Phase 3 data for essential tremor, NDA filed early 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Praxis Precision Medicines who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Stock Options

Company Equity

Performance Bonus

Unlimited Paid Time Off

Paid Holidays

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

-1%
Yahoo Finance
Mar 13th, 2026
Biotech Praxis secures $80.5M investment from Driehaus as stock soars 685% ahead of dual FDA filings

Driehaus Capital Management has invested $80.5 million in Praxis Precision Medicines, purchasing 432,510 shares and bringing its stake to 1.87% of assets under management. The transaction, disclosed on 17 February 2026, increased Driehaus's position value by $248.5 million, reflecting both the purchase and share price appreciation. Praxis shares have surged 685% over the past year to $303.37, giving the company an $8.4 billion market capitalisation. The biotech firm recently submitted two FDA applications: ulixacaltamide for essential tremor and relutrigine for rare developmental epilepsies. CEO Marcio Souza estimates the company's four late-stage programmes could generate over $20 billion in revenue if commercialised. Praxis ended 2025 with $926 million in cash and raised an additional $621 million in January, providing funding through 2028.

Intellectia.AI
Feb 16th, 2026
Affinity Asset Advisors Acquires New Stake in Praxis Precision Medicines

- **New Investment Disclosure**: On February 13, 2026, Affinity Asset Advisors disclosed a new position by acquiring 185,000 shares of Praxis Precisio...

Yahoo Finance
Feb 14th, 2026
Affinity Asset Advisors bets $55M on Praxis Precision Medicines as biotech surges 266% ahead of drug applications

Affinity Asset Advisors has disclosed a new position in Praxis Precision Medicines, acquiring 185,000 shares valued at $54.53 million during the fourth quarter. The stake represents 3.11% of the fund's reportable assets. Praxis shares were trading at $317.25 as of 13 February 2026, up 266% over the past year. The Boston-based clinical-stage biotechnology company develops therapies for central nervous system disorders, with lead candidates targeting major depressive disorder, essential tremor and epilepsy. The company expects two new drug application submissions by mid-February and holds approximately $956 million in cash and investments, sufficient to fund operations into 2028. Third-quarter research and development expense reached $65.8 million, whilst net loss widened to $73.9 million.

Praxis Precision Medicines
Feb 6th, 2026
Praxis Precision Medicines Announces $110 Million Financing - Praxis Precision Medicines, Inc.

Participation from top-tier healthcare investors recognizes momentum across breadth of its CNS therapeutics portfolio CAMBRIDGE, Mass.--Praxis Precision Medicines, Inc., a clinical-stage company translating genetic insights into the development of therapies for people with central nervous system

Praxis Precision Medicines
Feb 6th, 2026
Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Praxis Precision Medicines, Inc.

CAMBRIDGE, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced